{"id":"NCT04574999","sponsor":"Italfarmaco S.A","briefTitle":"Study to Determine Efficacy & Safety of a Low Concentration Estriol (0.005%) in Postmenopausal Vaginal Atrophy.","officialTitle":"Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicentre Study, to Determine Efficacy and Safety of a Low Concentration Estriol (ITFE-2026 0.005%) by Vaginal Route in the Treatment of Postmenopausal Vaginal Atrophy.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01-25","primaryCompletion":"2009-02-23","completion":"2009-02-23","firstPosted":"2020-10-05","resultsPosted":"2020-12-11","lastUpdate":"2020-12-11"},"enrollment":167,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Vaginal Atrophy"],"interventions":[{"type":"DRUG","name":"Estriol","otherNames":["16α-hydroxyestradiol or as estra-1,3,5(10)-triene-3,16α,17β-triol"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"0.005% Estriol group","type":"EXPERIMENTAL"},{"label":"Placebo group","type":"PLACEBO_COMPARATOR"}],"summary":"Randomized, double-blind, placebo-controlled multicentre study, with parallel groups, to determine the efficacy and safety of a new low-concentration estriol formulation (ITFE-2026 0.005%) for application by vaginal route in the treatment of postmenopausal vaginal atrophy.\n\nPrimary objective:\n\n• To evaluate the efficacy of 0.005% Estriol vaginal gel by evaluation of the change in the maturation value of the vaginal epithelium (MV) after 12 weeks of treatment.\n\nSecondary objectives:\n\n* To determine the variation of the vaginal pH, as well as symptoms and signs suggestive of vaginal atrophy after 12 weeks of treatment.\n* To study the variation of the MV, pH and symptoms and signs suggestive of vaginal atrophy after an initial observation period of 3 weeks.\n* To evaluate the safety of 0.005% Estriol vaginal gel\n* To evaluate the acceptability of 0.005% Estriol vaginal gel","primaryOutcome":{"measure":"Change From Baseline to Week 12 in Maturation Value (MV) After 12 Weeks of Treatment","timeFrame":"At week 12/Early withdrawal","effectByArm":[{"arm":"0.005% Estriol Group","deltaMin":26.9,"sd":23.33},{"arm":"Placebo Group","deltaMin":3.2,"sd":16.48}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":null,"sex":"FEMALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":13},"locations":{"siteCount":12,"countries":["Spain"]},"refs":{"pmids":["22914208"],"seeAlso":["https://journals.lww.com/menopausejournal/Abstract/2012/10000/The_therapeutic_effect_of_a_new_ultra_low.14.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":114},"commonTop":["Headache","Pruritus","Hot flush","Urinary tract infection","Vulvovaginal pruritus"]}}